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Effect of sympathetic nervous system mediators on the tumor microenvironment via
small extracellular vesicles in ovarian cancer
Sujanitha Umamaheswaran, BTech
Advisor: Anil K. Sood, MD

Background: Psychological stress can promote progression of gynecological malignancies
by increasing secretion of sympathetic nervous system (SNS) mediators, namely
catecholamines. However, the mechanisms underlying these effects are poorly explored.
Here, we examined the effect of stress hormones on small extracellular vesicles (EVs)
release in gynecological malignancies and the biological impact of these stress-conditioned
EVs on the tumor microenvironment.

Methods: Supernatants were collected from epithelial ovarian cancer cell lines treated with
norepinephrine, epinephrine or hydrocortisone. Small EVs were isolated from the
supernatants of these cell lines and assessed for number and particle size. Auto re-uptake
studies, invasion assays and tube formation assays were performed on ovarian cancer cells
and RF24 endothelial cells exposed to control and stress-conditioned EVs. Tipifarnib, a
farnesyl transferase inhibitor, was used to inhibit small EV secretion to study dependence of
outcomes of previously performed functional assays on EV number. Mass spectrometry
(MS) was performed on control and stress-conditioned small EVs to compare protein
content. In vivo Matrigel plug assay was performed to compare the angiogenic potential of
control and stress-conditioned EVs.
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Results: Addition of 1uM and 10uM of catecholamines and glucocorticoids increased small
EV secretion by ~ 4-fold in OVCAR5 and HeyA8 cell lines. Maximum increase in secretion
was seen between 8 hr and 24 hr after treatment with stress hormones, after which secretion
decreased. EV uptake experiments with ovarian cancer cells showed that the percentage of
uptake of stress-conditioned EVs at all timepoints was the same, around 65%, indicating that
the capacity of the cell to produce EVs might be decreasing after 24 hours. Stressconditioned EVs increased invasion of ovarian cancer cells and tube formation capacity of
RF24 cells by ~ 2-fold. In vivo analysis of the angiogenic potential of control vs stressconditioned EVs showed that stress-conditioned EVs induced more angiogenesis than
control EVs. MS analysis of EV contents from control and stress-conditioned EVs showed a
differential expression of angiogenesis and cell growth-related proteins in the stressconditioned EVs alone.

Conclusions: Our results demonstrate that addition of stress-hormones increases the
angiogenic potential of cancer cell-derived small EVs. Further exploration of the effects of
stress-conditioned small EVs on cancer cells and other cell types in the tumor
microenvironment and pathway analyses might uncover other mechanisms of stress-induced
cancer progression.
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Chapter 1 – Introduction
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1.1 Chronic stress
1.1.1 General Adaptation Syndrome
Stress response is a non-specific reaction of an organism to distress or threats
(1). The first observation of the effects of stressors such as exposure to cold, injury
or administration of different drugs on organisms was noted by Hans Selye in 1936
(2). While studying stress responses in rats, he observed three classic responses,
namely enlargement of the adrenal glands, bleeding in the gastrointestinal tract and
distorted lymphatic organs, observations that he associated with the General
Adaptation Response. He explained that this response occurred in three phases, the
alarm reaction, resistance stage and the exhaustion stage. The manifestations of the
alarm reaction include tissue catabolism, increased blood levels of corticoids and
lipid depletion from the adrenal glands. Following this, the resistance stage sets in
where there is an increased secretion of corticoids from the adrenal glands and
increased hormonal defense characterized by increased secretion of
adrenocorticotrophic hormone (ACTH). Finally, exhaustion stage sets in where the
defense mechanisms of the body are unable to fight the stressor. (3–5). Though
Selye’s studies concluded that stress hormones in the body run out post the chronic
stress episode, studies conducted subsequently indicated otherwise.

1.1.2 Responses to stress
Chronic stress is the non-specific response to a prolonged demand, which
could either be a physical or emotional strain. In both cases, the biological outcome
remains the same. Fight-or-flight responses are the acute responses that enable the
body to perceive a threat and defend itself. They are the responses that enable an
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organism to defend itself from an imminent threat, like an animal that has to run
away from its predator. These acute stress responses are short-lived and are
beneficial to the organism. Chronic stress on the contrary has more profound
biological implications and is more persistent than acute stress (6,7).

1.1.3 The biology of stress responses
The first organ to be activated in response to stress is the hypothalamus.
Irrespective of the of the source of stress, the response has 2 parts: the
sympathoadrenomedullary pathway (SAM) which produces norepinephrine (NE) or
the hypothalamic-pituitary axis (HPA) which produces cortisol. In SAM, the adrenal
medulla is activated by the hypothalamus which leads to secretion of the
catecholamines epinephrine and norepinephrine from the chromaffin cells. In the
HPA axis, the pituitary gland is activated by the hypothalamus to secrete ACTH
which stimulates the adrenal cortex to release corticosteroids (figure 1) (8,9). In
cancer patients, both cortisol and norepinephrine levels are elevated (10).
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Figure 1: Components of the stress system
(Antoni, Michael H., Susan K. Lutgendorf, Steven W. Cole, Firdaus S. Dhabhar,
Sandra E. Sephton, Paige Green McDonald, Michael Stefanek, and Anil K. Sood.
"The influence of bio-behavioural factors on tumour biology: pathways and
mechanisms." Nature Reviews Cancer 6, no. 3 (2006): 240-248. Used with
approval from Copyright Clearance Center. License number 4819030577334)
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Following a stressful situation, the body gets back to normal by making
biochemical or behavioral changes and this is termed as allostasis (11). The price
that the body pays by adapting to physical and emotional stress is called allostatic
load, as defined by Bruce McEwen in his work on neuropharmacology of the stress
response. He suggested that allostatic load could be a consequence of too much
stress or improper shutting down of the stress response process once the stressor has
passed (12). According to his work, there are 4 types of allostatic loads that are
observed in general (figure 2): in normal responses, the body returns to normal after
the stressor is removed. In abnormal cases, there may be a lack of adaptation that
prevents allostasis or the body is unable to respond appropriately. When the
biochemical machinery required to stop the response to stress is not triggered at the
right time, there is a prolonged allostatic load. Catecholamines increase the
production of pro-inflammatory cytokines via activation of the adrenergic receptor
beta-2 (ADRB2) while this production is inhibited by glucocorticoids. Inadequate
physiological responses are generated when there is a low production of
glucocorticoids during the stress response, thereby elevating pro-inflammatory
cytokines (11–15).
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Figure 2: Types of allostatic loads
(McEwen,

Bruce

S.

"Allostasis

and

allostatic

load:

implications

for

neuropsychopharmacology." Neuropsychopharmacology22, no. 2 (2000): 108. Used
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with

approval

from

Copyright

Clearance

Center.

License

number

4819030764521)

1.1.4 Role of catecholamines and glucocorticoids in the stress response
The initial response to any stressor causes an increase in the production of
catecholamines within the first 30 minutes of exposure. This leads to an increase in heart
rate and alertness via ADRB2 signaling. Glucocorticoids increase in the blood stream an
hour after the exposure to the stressor, mainly to facilitate recovery and terminate the
reaction to stress. Catecholamines and glucocorticoids are the most important molecules
involved in the stress response but they have different functions in the process.
Catecholamines are released when the sympathetic nervous system (SNS) is activated
and prepare the body to face the threat. This is accompanied by increase in heart rate,
increased blood supply to the muscles and breathing. Cortisol on the other hand
stimulates gluconeogenesis to meet the energy demands of the stress response process
and decreases immune function (16,17). The signaling pathways through which these
molecules operate are discussed in detail below.

1.1.5 Adrenergic signaling
Acute activation of the SNS by central nervous system (CNS) activity
increases circulating levels of catecholamines in the bloodstream. SNS nerve fiber
activity is not only regulated by the CNS but also by local regulatory processes,
thereby affecting catecholamine release. Because of this, the levels of norepinephrine
and epinephrine differ in the bloodstream and different tissue environments
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(7,18,19). Catecholamines signal through the 𝛼1, 𝛼2 and 𝛽 adrenergic receptors
which differ in the distribution across tissue types and their associated G-proteins. In
cancer, the subtypes of the 𝛽 adrenergic receptor, 𝛽1, 𝛽2 and 𝛽3 receptors, are
present in various cancer-related cell types such as epithelial cells, neural cells,
fibroblasts, cells of the vasculature as well as in most immune cell types (18,19). The
G-proteins that are associated with these adrenergic receptors are guanosine binding
domains downstream of the receptors that can either be coupled to cyclic adenosine
monophosphate (cAMP) leading to stimulatory (Gαs) or inhibitory (Gi) signaling, or
they can be coupled to phospholipase C (Gq). ADRB1 is coupled with Gas, ADRB2
to both Gαs and Gi and ADRB3 is coupled with Gi/nitrous oxide pathway. Coupling
with Gas increases cAMP levels, thereby binding to protein kinase A (PKA) to
release the activated catalytic subunit (figure 3). PKA then phosphorylates
serine/threonine residues on downstream effectors that have specialized PKA
binding motifs. These phosphorylation events have gene expression effects such as
phosphorylation of the transcription factor cAMP-responsive element binding
protein/activating transcription factor (CREB/ATF) family, which engages almost
20% of human genes. PKA can also activate 𝛽-adrenergic receptor kinase (BARK)
that activates the Src/Ras/mitogen-activated protein kinase (MAPK) pathway. cAMP
also mediates downstream effects through the nucleotide guanine exchange protein
activated by adenylyl cyclase (EPAC). EPAC brings about MAPK-mediated cell
growth and proliferation and also has effects on cell morphology, motility and
secretions (20–22). The downstream signaling effects of ADRBs can be blocked by
use of selective and non-selective 𝛽-blockers such as atenolol and propranolol.
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Figure 3: Adrenergic signaling pathway and its downstream events
(Cole, Steven W., and Anil K. Sood. "Molecular pathways: beta-adrenergic
signaling in cancer." Clinical cancer research18, no. 5 (2012): 1201-1206. Used
with approval from Copyright Clearance Center. License number
4819030898982)
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1.1.6 Glucocorticoid signaling
Biological functions of glucocorticoids (GCs) such as cortisol are elicited via
the glucocorticoid receptor (GR). In the absence of cortisol, GR is bound to different
molecules and is inactive. GRs mainly regulate gene expression and this occurs in
three distinct ways: the DNA binding domain of the receptor directly binds to DNA
sequences containing GR-responsive elements, activation of DNA via transcription
factors and alteration of kinases (23,24) (figure 4). Most of the transcription
enhancing functions of GRs are brought about via STAT family proteins. GRs are
potent mediators of anti-inflammatory processes, especially via the Nf-kB pathway.
Ailments caused by inflammation such as asthma and rheumatoid arthritis are treated
with glucocorticoids (25–28).
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Figure 4: Glucocorticoid signaling and its variations
(Liu, Bing, Tie-Ning Zhang, Jessica K. Knight, and Julie E. Goodwin. "The
Glucocorticoid Receptor in Cardiovascular Health and Disease." Cells 8, no. 10
(2019): 1227. Approved for use by MDPI Open Access)

1.1.7 Effect of chronic stress in disease
Acute stress is an adaptive response and is beneficial for the organism that is
preparing for an impending threat. Chronic stress however, if it persists due to
inadequate response or repeated exposure, can be physically detrimental. A prospective
study investigating the influence of life stress and social support on coronary heart
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disease incidence and mortality in 100 individuals found that individuals with high life
stress levels had 50% higher risk of disease incidence while individuals with inadequate
social support had up to 380% higher risk (29). Studies conducted by Glaser and
colleagues showed that humoral and cellular immune responses are suppressed in
individuals exposed to high psychological stress (30). Glaser’s studies also showed that
antibody titers following vaccination with Hepatitis B and/or influenza were low in
medical students with upcoming examinations and caregivers of Alzheimer’s disease
patients (31). Chronic stress was also observed to delay wound healing by 25% in
caregivers of Alzheimer’s disease patients with punch biopsy wounds, and these
individuals also had lower IL-1 levels in the blood (32). Chronic exposure to stress (for a
duration of one month or more) increased susceptibility to influenza virus infections, as
shown by a study conducted in 276 individuals. The individuals with greater levels of
psychological stress had higher mucus weights, IL-6 levels and greater viral infection
symptom scores (33). Broadly, elevated stress in the body brings about physiological
responses such as altered cardiovascular tone, increased blood pressure and heart rate,
impaired immune responses, increased gluconeogenesis and lipolysis and increased
respiratory rate.

1.1.8 Effect of chronic stress in cancer
There is growing evidence to show that biobehavioral factors and
neurohormonal changes influence risk of developing cancer and malignant
progression. Epidemiological data support that psychosocial factors influence cancer
onset and progression, as shown in this study which demonstrated that marital
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disruption increases the risk for developing breast cancer two-fold (34). However,
some studies have been inconclusive in finding substantial links between
psychosocial and increased cancer risk (35–37). Data from patients with existing
tumors indicate that cancer diagnosis and treatment contribute to distress which
might support progression of their disease (38). A prospective study in ovarian
cancer patients found that the median survival time for patients with low social
attachment was 3.35 years, as opposed to 4.70 years in patients with high social
attachment (39). Higher risk for ovarian cancer was determined in women socially
isolated or widowed women when these psychosocial stressors were experienced
many years prior to diagnosis, indicating that chronic stress has prolonged biological
impact (40).
In preclinical models of breast cancer, stresses like hypothermia, swim stress
and surgical stress increased incidence of lung metastases (41–43). Increased
metastasis was observed in vivo in murine models of ovarian cancer subjected to
restraint stress, through increased prostaglandin synthesis (44). Treatment of human
ovarian cancer cell lines with catecholamines showed an increase in the invasive
ability of these cells in vitro and chronic restraint stress has been shown to increase
tumor growth and angiogenesis in vivo in murine models of human ovarian cancer
(45,46). In an experimental model of colon cancer, norepinephrine increased
invasion of cancer cells in vitro, and this effect was inhibited on treatment with
atenolol and propranolol, thereby establishing that catecholamines promote processes
essential for tumor growth and metastasis. (47). Similarly, norepinephrine was
shown to upregulate vascular endothelial growth factor (VEGF) in ovarian cancer
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cell lines via the ADRB-cAMP-PKA pathway, and this effect was blocked by the 𝛽blocker propranolol and promoted by the 𝛽-agonist isoproterenol (48,49).
In the clinic, a retrospective study with 1,413 triple-negative breast cancer
patients found that use of 𝛽-blockers along with neoadjuvant chemotherapy was
associated with better relapse-free survival (50). A study with 2,394 pancreatic
ductal adenocarcinoma patients found that individuals who used 𝛽-blockers (n=522)
had lower cancer-specific mortality rate when compared to non-users, especially the
patients with localized disease (51). Several studies in ovarian cancer patients have
indicated that the use of beta-blockers like propranolol improve outcome in patients.
In a study by Ramondetta and colleagues, it was observed that patients with
suspected diagnosis of epithelial ovarian cancer who received propranolol during
primary treatment had higher quality of life and improvements in anxiety scales (52).
A prospective pilot trial with women having stage II-IV epithelial ovarian cancer
showed that combining propranolol with chemotherapy decreased expression of proinflammatory genes and improved depression and quality of life(53). In a
retrospective analysis, use of non-selective beta blockers in patients with ovarian
cancer was associated with improved progression-free survival (54).
The glucocorticoid receptor (GR) activity has been shown to be protumorigenic in cancer by many studies. There is data to show that GR activation in
breast cancer cells causes transactivation of genes encoding anti-apoptotic pathways
such as MKP-1 and SGK-1 (55). A meta-analysis from 1,378 early stage breast
cancer patients indicated that high levels of GR expression correlated with shorter
progression free survival in estrogen receptor-negative (ER-) patients who were
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treated or untreated with adjuvant chemotherapy. Gene expression analysis showed
increased activation of EMT, inflammation and cell adhesion-related pathways in
ER- tumors expressing high levels of GR (56). In prostate cancer, GR expression
increases in a subset of tumors following androgen deprivation therapy and this has
been shown to reduce the efficacy of the androgen receptor antagonist MDV3100,
thereby increasing tumor cell viability (57). Combining the GR antagonist
mifepristone with dexamethasone or paclitaxel treatment was observed to
significantly reduce tumor burden in xenograft models of the triple negative breast
cancer cell line MDA-MB-231 (58).
Collectively, these studies indicate that stress and sympathetic nervous
system activity promote malignant progression and are detrimental to patient
outcomes. However, specific mechanisms of this process and novel therapeutic
targets in the stress response pathway are yet to be identified.
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Figure 5: Effects of psychosocial factors on the tumor microenvironment
(Costanzo, Erin S., Anil K. Sood, and Susan K. Lutgendorf. "Biobehavioral
Influences on cancer progression." Immunology and Allergy Clinics 31, no. 1 (2011):
109-132. Used with approval from Copyright Clearance Center. License
number 4819031090727)

1.2 Extracellular vesicles
1.2.1 Discovery
The first existence of membrane-enclosed particles outside cells was reported
almost 50 years ago, in solid tissues such as cartilage and in biological fluids like
blood or semen (59–61). Since then, studies have shown that the process of secreting
lipid-enclosed vesicles from cells is conserved across organisms, including all
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eukaryotes and prokaryotes (62). Extracellular vesicles (EVs) have been isolated
from several bodily fluids like amniotic fluid, cerebrospinal fluid, ascites, bile, urine
and saliva. EVs have also been classified based on their origin and size into various
sub-types such as microparticles, microvesicles (MVs), nanoparticles and exosomes.
Extracellular vesicles (EVs) were initially assumed to be formed due to outward
budding of the plasma membrane. However, studies conducted in the 1980s showed
a mechanism involving formation of intracellular vesicles which then get secreted by
fusing with the plasma membrane. To investigate the loss of transferring receptors
(TfR) in reticulocytes, the groups of Stahl and Johnstone used gold particle-bound
transferrin to study the endocytosis and trafficking of TfR via electron microscopy.
They found that the receptor was associated with endosomes containing multiple
small internal bodies with sizes in the range of nanometers. The small particles were
then observed to be released on fusion of the endosome with the plasma membrane
(63–65). These studies suggested that this unique form of secretion was the
mechanism by which plasma membrane components were discarded from cells.
The first reports of exosomes and extracellular vesicles not merely being
involved in disposal of unwanted cellular components came from Théry and
colleagues. They found that exosomes secreted by Epstein-Barr virus (EBV)
transformed B cell lines had major histocompatibility complex (MHC) class II
molecules. Their data indicated that these exosomes were of endosomal origin and
their protein content was different from that of the plasma membrane, ruling out the
possibility that they were formed by shedding of the membrane. These B cell
exosomes also had the capacity to stimulate CD4+ T cell responses in vitro. To build
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on these findings, the group also showed that dendritic cell-derived exosomes had
the ability to suppress the growth of established tumors in vivo (66,67). These studies
were important in demonstrating that extracellular vesicles are capable of eliciting a
biological response.

1.2.2 Nomenclature of extracellular vesicles
The terms exosome, ectosome, shedding vesicle, MV and microparticle refer
to particles in the size range of 150 – 1,000nm released by shedding of the plasma
membrane. Trams and colleagues first used the term “exosome” to refer to vesicles
having size 40 – 1,000nm and 5’-nucleotidase activity isolated from various cultured
cells (68). Later, Johnstone and colleagues adopted the term exosome for particles of
endosomal origin having size 30 – 100nm that are released as a consequence of
multivesicular bodies (MVBs) fusing with the plasma membrane (65). Since then,
many studies used the term “exosomes” to refer to EVs and were assumed to
correspond to intraluminal vesicles (ILVs) of MVBs. The nomenclature surrounding
extracellular vesicles and exosomes has been under debate due to unclear
demarcations in size ranges, structure, protein composition and buoyant density.
However, the new guidelines provided by the International Society for Extracellular
Vesicles (ISEV) in 2019 now suggest that the term “extracellular vesicle” should be
used for lipid bilayer-enclosed particles released from the cell instead of using the
term “exosome”. Furthermore, ISEV guidelines suggest the use of the term exosome,
small EV and large EV only after ascertaining the size of the particle. Particles with
size ranging from 30 – 50nm are to be called exosomes. Small EV is the suggested
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term for particles with size 60 – 200nm. Particles larger than this size range are to be
called large EVs. Finally, any particle that is released from the cell which is larger
than a nanoparticle is to be referred to as a microparticle (69,70).

1.2.3 Characterization of EVs
Proteomic analyses have indicated some commonly expressed proteins in EV
samples, however these cannot be used as EV markers since different subsets of EVs
contain different enriched proteins. So ISEV laid out some guidelines for the
characterization of EVs based on protein content (figure 6). The guidelines suggest
that there should be a two-step characterization of proteins in EVs based on the
source cell: proteins that are expected to be enriched in the EVs and the proteins that
should not be expected to be enriched in EVs of endosomal origin.

Figure 6: Guidelines for EV characterization based on protein content
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(Lötvall, Jan, Andrew F. Hill, Fred Hochberg, Edit I. Buzás, Dolores Di Vizio,
Christopher Gardiner, Yong Song Gho et al. "Minimal experimental requirements for
definition of extracellular vesicles and their functions: a position statement from the
International Society for Extracellular Vesicles." (2014): 26913. Used with
permission from Journal of Extracellular Vesicles)

Analytical approaches like western blots, high resolution flow cytometry and mass
spectrometry proteomic analyses are employed for characterization of the protein
content in EVs. For single vesicle characterization, high resolution microscopy
techniques like transmission electron microscopy (TEM) or atomic force microscopy
(AFM) are employed. Size distribution studies on EVs are performed by nanoparticletracking analysis, dynamic light scattering and resistant pulse sensing (71). A novel
high-resolution flow cytometry-based technique can distinguish particles that are
<300nm in size and this can also be employed to confirm the presence of EVs (72).

1.2.4 Isolation of EVs
The protocol used by Johnstone and Raposo to isolate exosomes from
reticulocytes has been described in detail by Théry and colleagues (73). This
protocol is based on a series of low speed centrifugation and ultracentrifugation steps
(figure 7). Before ultracentrifugation, the low speed centrifugation helps to eliminate
larger sized particles, cell debris and apoptotic bodies. Filtration of the supernatant
through 0.22µm filters or size-exclusion chromatography can be done to eliminate
particles greater than 200nm in size. When ultracentrifugation at 100,000 x g is
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performed, vesicles of different sized as well as protein aggregates tend to sediment
together, and the vesicles can be separated from the protein by a sucrose gradient.
The proteins sediment through the gradient whereas lipid containing particles float
upwards. Besides these steps, commercially available easy isolation kits can also be
used to isolate EVs from culture media or biological fluids.

Figure 7: General EV isolation protocol
(Théry, Clotilde, Sebastian Amigorena, Graça Raposo, and Aled Clayton. "Isolation
and characterization of exosomes from cell culture supernatants and biological
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fluids." Current protocols in cell biology 30, no. 1 (2006): 3-22. Used with
permission from Current Protocols)

1.2.5 Composition of EVs
EVs are composed of a lipid bilayer which encloses a variety of proteins and
other molecules such as nucleic acids and lipids (figure 8). Proteomic studies on EVs
have shown that some specific contents in the EVs depend on the type of cell that
secretes them, while the rest are found in most EVs irrespective of the source. These
include plasma membrane components and proteins from the endosome and cytosol.
EVs however do not contain organelles like mitochondria, endoplasmic reticulum
and the Golgi apparatus or their associated proteins (69). Some of the membraneassociated proteins that are enriched in EVs include tetraspanins like CD63, CD81,
CD82 and CD53, which are also considered to be markers for the plasma membrane
and early endosomes (74). EVs also contain proteins that associate with lipid rafts
like flotillin and glycosylphosphatidylinositol-anchored proteins (75,76). Lipids such
as cholesterol, ceramides, saturated and monounsaturated fatty acids and
sphingomyelin are abundant in EVs (62,75,77,78).
A major breakthrough in the study of EV composition was achieved when
Ratajczak and Valadi showed that mRNA and miRNA can be present in EVs, and
that target cells of EVs could translate EV-associated mRNA into protein (79,80).
Subsequent studies showed the presence of mRNA in EVs from bodily fluids as well
(81,82). Deep sequencing approaches have found that EVs also contain small noncoding RNAs like tRNA fragments, vault RNA, small interfering RNAs (83,84). The
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RNA isolated from EVs was also found to have a similar profile to that of the cells of
origin (79,80). Many studies did not demonstrate if the identified RNA from EVs
were truly from the EVs or from protein aggregates that sedimented with EVs during
ultracentrifugation. However, buoyant density separation of EVs post
ultracentrifugation could eliminate extracellular RNA species. (69).

Figure 8: Molecular composition of EVs
(Colombo, Marina, Graça Raposo, and Clotilde Théry. "Biogenesis, secretion, and
intercellular interactions of exosomes and other extracellular vesicles." Annual
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review of cell and developmental biology 30 (2014): 255-289. Used with approval
from Copyright Clearance Center - 1032052)

1.2.6 Biogenesis of EVs
The first step in the process of EV biogenesis is the formation of MVBs
through the endosomal pathway. The inward budding of the plasma membranes and
its associated machinery leads to the formation of endosomes. The endosomal
membrane pinches into the endosomal lumen, leading to segregation of cargo and
formation of small ILVs. This occurs when the endosomal sorting complex
responsible for transport (ESCRT)-0, -I, -II and -III become active and associate with
accessory proteins such as Alix and VPS4 (figure 9). ESCRT-0 recognizes and
sequesters ubiquitinated proteins on the endosomal membrane. ECSRT-I and -II are
responsible for the inward budding of the endosomal membrane and sorting of the
cargo, while ESCRT-III is responsible for the scission of endosomal membrane to
form ILVs. The ILVs enclosed within the endosomal membrane collectively form
MVBs. However, there is data to suggest that MVB formation occurs even in the
absence of the ESCRT complex, when all four subunits are depleted (85,86).
Proteins like tetraspanins and MHC class II molecules are enriched in EVs and have
been shown to have a function in the formation of ILVs (87,88).
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Figure 9: Biogenesis of MVBs
(Colombo, Marina, Graça Raposo, and Clotilde Théry. "Biogenesis, secretion, and
intercellular interactions of exosomes and other extracellular vesicles." Annual
review of cell and developmental biology 30 (2014): 255-289. Used with approval
from Copyright Clearance Center - 1032052)

Some components of the ESCRT complex have been show to play a role in
EV formation and secretion. The accessory protein Alix is known to interact with
TfR in reticulocytes to aid in EV formation (89). Hepatocyte growth factorassociated tyrosine kinase (Hrs), a component of ESCRT-0 is known to regulate EV
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formation and secretion in dendritic cells (90). The tumor suppressor p53 along with
its transcriptional target TSAP6 and the ESCRT-III component Chmp1A also
regulates MVB and EV biogenesis (91,92). The mechanism of incorporation of
cytosolic components into EVs is not fully understood but studies suggest that EV
membrane proteins associate with chaperone proteins like Hsc70, Hsp90, 14-3-3
epsilon and PKM2, leading to sorting of cytosolic proteins into EVs (88,89).

1.2.7 Release of EVs into the extracellular space
EVs are released into the extracellular space by fusion of the MVBs to the
plasma membrane (figure 10). This process requires actin, microtubules, kinesins,
myosins, GTPase switches and fusion machinery such as SNARE proteins (62,93).
Rab27a and Rab27b are important for secretion of EVs, and their knockdown
significantly reduced EV release. Rab27a also functions alongside secretorylysosome-related organelles, indicating its presence in the endocytic compartment
involved in EV release. Silencing of Rab27 effectors Slp4 and Slac2b inhibited EV
release, similar to the results seen with Rab27a/b knockdown (94,95). In another
study, knockdown of Rab GTPase activating proteins reduced EV secretion (96). The
SNARE complex of proteins is involved in the Ca2+ regulated exocytosis of
conventional lysosomes and also includes the proteins VAMP7 and synaptotagmin
VII (97). It is believed that the fusion of MVBs to the plasma membrane is
modulated by the same machinery because EV secretion in reticulocytes is
dependent on VAMP7 (98), and modification of the Longin domain of VAMP7
impaired lysosomal secretion but not EV release (99). Studies have also shown that
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Wnt-containing EVs require R-SNARE Ykt6 for secretion (100). In summary, the
Rab GTPases and the SNARE family of proteins have an important role to play in
the release of EVs from MVBs into the extracellular space.

Figure 10: Release of EVs into the extracellular space
(Hessvik, Nina Pettersen, and Alicia Llorente. "Current knowledge on exosome
biogenesis and release." Cellular and Molecular Life Sciences 75, no. 2 (2018): 193208. Approved for use by Creative Commons CCBY License)

1.2.8 EVs in cancer
EVs have been described in the literature mainly as promoters of tumor
progression. Due to their presence in different biological fluids, cancer EVs may be
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used as a diagnostic tool to detect glioblastoma, melanoma, ovarian cancer, breast
cancer and prostate cancer (101–106). Studies have reported high concentrations of
EVs in the circulation of patients having breast, ovarian and pancreatic cancer
(101,107). EVs also can contain nucleic acids to serve as cancer biomarkers, like the
mutant mRNA of EGFRvIII in glioblastoma EVs (106). miR-21 and miR-141 have
been shown to be elevated in patients with advanced esophageal cancer and
metastatic prostate cancer respectively (108,109). EV-derived proteins can also serve
as a means of detecting cancer, as shown in a study where stage 3 and stage 4
melanoma patients had high EV-associated MET and phospho-MET when compared
to healthy subjects (110). In the microenvironment, EVs from cancer cells and the
surrounding immune and vascular cells play roles in generating a pro-tumor and antitumor niche by influencing host responses. EVs may aid immune evasion by
impairing dendritic cell maturation through upregulation of IL-6 in bone marrow
precursor cells (111). Cancer cell-derived EVs are also known to contain the Fas
ligand which can trigger apoptosis in Fas+ T cells (112). TGF-beta present in cancer
EVs can induce Tregs (113). Conversely, EVs from immune cells like dendritic cells
have been being investigated for antitumor activity in patients with non-small-cell
lung cancer (114).
EVs from cancer cells have the capacity to promote angiogenesis. Melanomaderived EVs have been demonstrated to induce vascular leakage and drive bone
marrow progenitor cells to a pro-vascular phenotype (110). Epithelial cell integrity is
also affected by cancer cell EVs containing miR-105 which downregulates tight
junction proteins to increase metastatic dissemination (115). Processes like
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tumorigenesis are also affected by EVs, with data to show that cancer EVs with
RISC-associated miRs can induce tumor formation in non-cancerous mouse
mammary cells (116). Tumor cell-derived EVs have also been implicated in
promoting therapy resistance. Studies have found cisplatin and doxorubicin in
cancer-cell derived EVs post treatment, indicating that efflux of drugs via EVs could
be a mechanism of drug resistance (117,118). HER-2+ EVs from HER-2
overexpressing breast cancer cells has been shown to inhibit the anti-proliferative
activity of trastuzumab, and removal of HER-1+ EVs from the blood might improve
outcome of HER-2 overexpressing tumors to trastuzumab (119,120).
The effect of psychosocial factors and stressors on EV cargo was investigated
by Lutgendorf and colleagues in ovarian cancer. EVs were isolated from the plasma
of 40 women with high grade ovarian cancer prior to surgery and were analyzed
based on the extent of social support the patients had. Trancriptomic analyses on the
EVs indicated an upregulation of mesenchymal-characteristic genes and CREB/ATF
family of transcription factors in the patients with low social support (121). Another
study showed that stressors such as inverting dark-light cycles in mice changed the
cargo of plasma EVs, making the EVs induce systemic inflammation and alter the
expression of circadian clock genes (122). These studies indicate that biobehavioral
factors could influence the cargo and the biological function of EVs. This is an
important observation since this gives rise to the possibility of the biological effects
of stress signaling being mediated through EVs.

29

Chapter 2 – Rationale, aims and significance
There is an abundance of clinical, experimental and epidemiological evidence to show
that human health is adversely affected by psychological and psychosocial factors. There is
an increased risk of incidence of cardiovascular disease, diabetes, inflammatory bowel
disease and cancer on exposure to chronic stress. Changes in the psychological state due to
stress causes an increase in catecholamines secretion by the adrenal gland or by local
production in the peripheral nerves. Various groups have produced data that indicate that
cancer cells and other microenvironment cell populations like immune cells, endothelial
cells and fibroblasts have receptors for catecholamines, and stimulation of these receptors
leads to tumor growth, angiogenesis and immune evasion. However, the exact mechanisms
of catecholamine-driven malignant progression are not fully known. For this project, we
sought to find a link between stress mediated ovarian cancer progression and small
extracellular vesicles (EVs), which are nanoparticles derived from the endocytic system of
the cell and are implicated in various biological processes like tumor growth, metastasis
promotion and inflammation. I hypothesized that catecholamines can increase the release
and oncogenic potential of small EVs from ovarian cancer cells. The aims of my study are:
1. To determine the effect of stress hormones (norepinephrine, epinephrine and
cortisol) on small EV release from cancer cells
2. To study the effects of stress-conditioned cancer EVs on the tumor
microenvironment
My work demonstrates that 1) catecholamines promote release of small EVs from human
high grade serous ovarian cancer cells and 2) the small EVs derived from catecholamine-
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treated cancer cells have increased capacity to drive processes like invasion and
angiogenesis in comparison to small EVs from untreated cancer cells. This work provides
evidence that stress and catecholamine-driven progression in ovarian cancer occurs via small
EVs.
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Chapter 3 – Methods
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3.1 Cell lines
High grade serous ovarian cancer cell lines (HeyA8, OVCAR5) and endometrioid
cell lines (A2780) were used in this study. A2780 and HeyA8 cell lines were maintained in
RPMI-1640 medium supplemented with 15% fetal bovine serum and 0.1% gentamycin
sulfate at 37°C. OVCAR5 cell line was maintained in DMEM-high glucose medium
supplemented with 10% fetal bovine serum and 0.1% gentamycin sulfate. All cells were
grown in at 37°C in a 5% CO2 -containing humidified incubator. For all in vitro
experiments, cancer cells were grown till 80% confluence and were serum-starved overnight
before treatment with drugs.

3.2 Drugs
Norepinephrine (NE) (1µM/10µM; Sigma-Aldrich, St Louis, MO, USA) was
dissolved in sterile PBS just before being added to the cells. Hydrocortisone, which is the
commercially available formation of cortisol(1µM/10 µM; Sigma-Aldrich, St Louis, MO,
USA), was dissolved in DMSO before being added to the cells. Tipifarnib and ketoconazole
stocks (in DMSO) were provided by Dr. Marc Ferrer from National Center for Advancing
Translational Sciences, for inhibiting secretion of EVs. 50nM of ketoconazole and/or 80nM
of tipifarnib were added to ovarian cancer cells 2 hours before adding NE for EV secretioninhibition studies. Control cells were treated only with vehicle, either DMSO or PBS.

3.3 Timepoints for medium isolation
For short-term exposure to NE and hydrocortisone, the supernatants were isolated at
6 hrs and 12 hrs after initial stress hormone treatment. For long term exposure to stress
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hormones, the cells were re-treated with stress hormones at 12 hrs after initial treatment.
Supernatant was isolated at 24 hrs and 48 hrs post initial treatment. Different controls were
used for all the timepoints. In the experiments involving serial isolation of media, the same
set of cells were used to obtain EVs from all the timepoints.

3.4 Isolation of small EVs
Standard methods suggested by the International Society of Extracellular Vesicles
were implemented in this study (73). Cell lines described above were grown in the
corresponding medium till 80% confluence was achieved. After overnight serum starvation,
the stress hormones were added to the cells. Conditioned medium was isolated at the
timepoints described above and was subjected to serial centrifugation. First, the medium was
centrifuged at 300g for 10min to pellet floating cells. Next, the supernatant was spun at
2000g for 20min to remove cell debris. The resulting supernatant was filtered through a
0.22µm filter (SCGPU05RE and SLGP033RS, Millipore-Sigma) to remove large-sized
vesicles. The medium was then subjected to ultracentrifugation at 40,000rpm for 1.5 hours
at 4°C in a Beckman Coulter Optima XE ultracentrifuge with a Ti 45 rotor (339160,
Beckman Coulter). The EV pellet was collected and resuspended in 3mL of PBS and spun at
the same speed for the same duration of time (123). The final pellet was resuspended in PBS
and stored at -20°C.

3.5 Small EV quantification
Small EV size and concentration was determined using nanoparticle tracking
analysis (NTA) with a NanoSight NS300 instrument (Malvern Panalytical). Protein
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concentration of small EVs was determined using a QubitTM Flex Fluorometer (Q33327,
Thermo Fisher Scientific) and QubitTM protein assay kit (Q3321 and Q33212, Thermo
Fisher Scientific).

3.6 Western Blot
Small EVs were spun down at 40,000rpm for 1.5 hours to pellet them. The
supernatant was discarded and the EVs were lysed with radioimmunoprecipitation assay
buffer (RIPA) [150mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, 25mM pH 7.5 tris,
1% Triton X-100] along with phosphatase and protease inhibitors (78442, Thermo Fisher
Scientific). Protein concentration was determined using QubitTM protein assay kit as
described above. For all blots, 10µg of EV-protein was used. EV lysate was diluted with 2x
Laemmli sample loading buffer (1610737, Bio-Rad) and was loaded on to 10% SDS
polyacrylamide gels. Separated proteins were transferred to a nitrocellulose membrane on
ice and blocked with 5% nonfat dry milk (AB10109-01000, AmericanBio) in TBS-T (0.1%
Tween-20) for 1 hr at room temperature after the transfer. Primary antibodies were diluted in
5% milk and TBS-T and were added to the membrane with overnight incubation at 4°C with
agitation. Post incubation, the membrane was washed with TBS-T three times with agitation
and the secondary antibodies were added (NA931V and NA934V, GE Healthcare) in the
ratio of 1:2500 in 5% milk in TBS-T for 1hr at room temperature with agitation. Membrane
was washed again with TBS-T and was developed using Western Lightning Plus ECL
(NEL105001EA, PerkinElmer) on X-ray films (F-BX57, Phenix). The antibodies used were
CD63 (1:3000, EXOAB-CD63-1, System Bioscience) and vinculin (1:2000, V9131, Sigma
Aldrich).
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3.7 EdU cell proliferation assay
HeyA8 cells grown on 6-well plates were treated with 1µM/10µM NE after
overnight serum starvation. 2hrs post NE treatment, 10µM of EdU was added to the cells
and incubated for 1hr. The cells were trypsinized, fixed, permeabilized and stained using the
protocol for the Click-iT Plus EdU Alexa Fluor 488 flow cytometry kit (C10632, Thermo
Fisher Scientific). EdU+ cells were counted using a Gallios flow cytometer at the MD
Anderson Cancer Center South Campus Flow Cytometry Core.

3.8 Invasion assay
Invasion of OVCAR5 and HeyA8 cells was measured in vitro. Inserts (8µm,
Millipore, Billerica, MA, USA) were coated with 0.7mg/mL of Matrigel (354234, Corning).
50,000 cells and 20µg of EV protein were placed in the upper chamber and were allowed to
move towards serum-containing media in the lower chamber. Invasion was assessed after
24hrs by fixing the cells in Protocol hema3 (Thermo Fisher Scientific). Cells were counted
in high-power fields and reported as average number of cells.

3.9 Tube formation assay
Growth factor reduced Matrigel (356231, BD Bioscience) was thawed on ice and
applied with pre-cooled pipettes to the inner well of 15µ-angiogenesis slides (81506, Ibidi)
and allowed to polymerize at 37°C in the presence of moisture. 10,000 RF24 endothelial
cells exposed to either control or stress-derived small EVs (20µg protein) were added to the
outer well of the slide, above the polymerized Matrigel. The cells were suspended in serum-
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containing media. Tube formation was observed after 8hrs and digital pictures were
captured. Quantification was done by counting the branching points from tubes formed by
discrete endothelial cells in each well.

3.10 Uptake of small EVs by cancer cells
100,000-300,000 ovarian cancer cells were added to coverslips in a 6-well plate. On
attainment of 80% confluence, they were serum starved overnight and treated with 10µM
NE. After 12 hrs/48 hrs, 5x109 – 1x1010 EVs labelled with CellMask Deep Red plasma
membrane stain (Thermo Fisher Scientific) were added to the cells. Prior to being added to
the cells, the EVs were incubated with the stain for 30min at 37°C and washed by spinning
them down in PBS at 40,000 rpm for 1.5 hrs. Upon addition of labelled EVs, the cells were
incubated at 37°C for 6 hrs. The supernatant was removed and the cells were washed with
PBS twice. 4% paraformaldehyde was added to the cells and incubated at room temperature
for 10-15 mins. The cells were washed three times with PBS, for 5 minutes each. DAPI was
added to the cells and incubated at room temperature for 20 minutes (1:1000, Sigma
Aldrich). The cells were then washed three times with PBS, for 5 minutes each. The
coverslips were then mounted on slides using ProLong Diamond Antifade Mountant
(Thermo Fisher Scientific) and were imaged with an Andor Revolution XDi Spinning Disk
confocal microscope.

3.11 Matrigel Plug Assay
All animal experiment protocols were approved by the University of Texas MD
Anderson Cancer Center. Matrigel plug assay was performed to compare the angiogenic
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potential of control and stress-derived small EVs. Nude mice were injected subcutaneously
with 2:3 ratio of growth factor reduced Matrigel (356231, BD Bioscience) and either serum
free RPMI-1640, conditioned media from control cells, conditioned media from NE-treated
cells or VEGF-A (BT293-010, R&D Systems; 400ng/mL in PBS per mouse). Total injection
volume was 500µL and all injections were prepared on ice to prevent polymerization of the
Matrigel. At day 8 post injection, the mice were taken down and the Matrigel plugs were
isolated and snap frozen in liquid nitrogen. Hemoglobin estimation of the plugs was
performed using the protocol provided with the QuantiChrom Hemoglobin Assay kit
(DIHB-250, BioAssay Systems).

3.12 Mass spectrometry (MS) analysis
20-40µg of intact EVs from OVCAR5 cells with or without 10µM NE treatment
were used for MS analysis. The protein content was quantified using QubitTM Flex
Fluorometer (Q33327, Thermo Fisher Scientific) and QubitTM protein assay kit (Q3321 and
Q33212, Thermo Fisher Scientific). The samples were sent to the MD Anderson South
Campus Proteomics Core for analysis. MS protocol was carried out as enlisted in (123).
Raw data was analyzed using Ingenuity Pathway Analysis (IPA).

3.13 Statistical analyses
All analysis was done on MS Excel or GraphPad Prism. Continuous variables were
compared with analysis of variance (ANOVA) or two-tailed t-test. Differences with respect
to controls were compared with the Mann-Whitney test. We considered p<0.05 to be
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statistically significant and all results were expressed as mean +/- standard mean error.
Sample sizes for all experiments are indicated in the results.
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Chapter 4 – Results
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4.1 Effect of norepinephrine on cell proliferation
Since one of the aims of this project is to study the effect of small EV release from
ovarian cancer cells on exposure to NE, it was important to determine if NE had any effect
on cell proliferation, which in turn could affect small EV number. HeyA8 cells were grown
in 6-well plates and were treated with 1µM or 10µM NE after overnight serum starvation.
2hrs post treatment with NE, EdU was added to the cells and incubated for one hour at 37°C.
The cells were then trypsinized, permeabilized and stained as per the Click-iT Plus EdU
Alexa Fluor 488 kit. EdU+ cells were measured by flow cytometry, which quantitatively
represents proliferating cells. It was observed that there was no significant increase in cell
proliferation of HeyA8 cells on addition of 1µM or 10µM NE (figure 11) [p=0.99, N=4].

Figure 11: Effect of NE on HeyA8 cell proliferation.
There was no significant increase in cell proliferation on addition of 1µM or 10µM of NE
on HeyA8 cells (p=0.99, N=4).
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This proved that any changed that might be observed in small EV numbers after treating
cancer cells with 1µM or 10µM NE is not because of NE-induced changes in cell number.

4.2 Confirmatory tests for EVs
EVs were isolated from the cell culture supernatants of OVCAR5 and HeyA8 cells
treated with 1µM or 10µM NE or hydrocortisone at different timepoints. In order to ensure
that the isolated pellets contained EVs, western blot analysis was performed to probe for
CD63, a tetraspanin molecule which is a marker for particles that are derived from the
endocytic system of the cell (figure 12). Nanoparticle tracking analysis was performed on
the EVs, and the size range of the particles was found to be between 60-200nm, indicating
that the isolated were small EVs (figure 13).

Figure 12: CD63 in EV samples.
EVs from control and NE-treated cells expressed CD63, indicating that NE treatment does
not alter the endocytic origin of cancer cell EVs.
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Figure 13: Particle size range of EVs.
EVs were found to have size between 67-200nm. Data was obtained by nanoparticle
tracking analysis.

4.2 Short-term exposure of ovarian cancer cells to norepinephrine and hydrocortisone
HeyA8 and OVCAR5 cells were treated with 1µM or 10µM NE or hydrocortisone
post overnight serum starvation. For the short-term time points, supernatants were isolated
from cells at 6 hrs and 12 hrs post treatment of the stress hormones. At 6 hrs, secretion of
small EVs decreased upon addition of increasing concentrations of stress hormones, in both
cell lines. This observation was reversed at 12hrs, where there was an increase (~2 fold)
with respect to controls in the release of small EVs with increasing concentrations of stress
hormones (figures 14, 15).
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Figure 14: Small EV release from OVCAR5 after short-term exposure to norepinephrine
and cortisol.
At 6 hrs post treatment, small EV secretion from OVCAR5 cells decreased on exposure to
increasing concentrations of NE and hydrocortisone. At 12 hrs, there was a significant
increase in small EV secretion on exposure to NE and hydrocortisone (p<0.0001, N=3).

Figure 15: Small EV release from HeyA8 after short-term exposure to norepinephrine
and cortisol.
At 6 hrs post treatment, small EV secretion from HeyA8 cells decreased on exposure to
increasing concentrations of NE and hydrocortisone. At 12 hrs, there was a significant
increase in small EV secretion on exposure to NE and hydrocortisone (p<0.005, N=3).

44

4.3 Long-term exposure of ovarian cancer cells to stress hormones
For the long-term exposure of the ovarian cancer cells to stress hormones, OVCAR5
and HeyA8 cells were treated with the stress hormones twice, with a repeated treatment at
12 hrs post the initial treatment. This was done because of the very short half-life of
norepinephrine and cortisol in vitro. Supernatants were isolated from cells at 24 hrs and 48
hrs post the “first” stress hormone treatment. At 24 hrs, it was observed that small EV
secretion increased with respect to controls (~2 fold) in on addition of increasing
concentrations of norepinephrine and hydrocortisone in both cell lines. At 48 hrs, however,
small EV secretion decreased with increasing concentrations of norepinephrine and
hydrocortisone, possibly due to auto-uptake or a reduction in the production of EVs within
the cell after this duration (figures 16, 17).

Figure 16: Small EV release from OVCAR5 after long-term exposure to norepinephrine
and cortisol.
Small EV secretion from OVCAR5 cells significantly increased on exposure to increasing
concentrations of norepinephrine and hydrocortisone at 24 hrs. However, at 48 hrs, there
was a decrease in the small EV secretion even on exposure to increasing amounts of the
stress mediators (p<0.0001, N=3).
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Figure 17: Small EV release from HeyA8 after long-term exposure to norepinephrine and
cortisol.
There was a significant increase in small EV secretion by HeyA8 cells at 24 hrs post
exposure to increasing concentrations of norepinephrine and hydrocortisone. At 48 hrs,
however, the small EV secretion decreased (p<0.0001, N=3).

4.4 Role of ADRB2 in promoting small EV secretion
To confirm if the increase in small EV secretion upon treatment with increasing
concentrations of stress hormones was occurring due to ADRB2-mediated signaling, I
performed the EV isolation studies done before in the A2780 cell line which is null for the
ADRB2 receptor (46). Here, instead of using different sets of cells for the different shortterm and long-term time points, the same cells were used at all timepoints, with
replenishment of media after supernatant isolation every time. It was observed that there is
no significant increase in the small EV secretion with respect to controls on addition of
stress hormones, at all timepoints (figure 18). This indicated that the ADRB2 receptor is
necessary for the increase in small EV secretion from ovarian cancer cells in response to
norepinephrine treatment.
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Figure 18: No change in small EV secretion in A2780 cells treated with norepinephrine.
There was no significant increase in small EV secretion in A2780 cells on treatment with
increasing concentrations of norepinephrine (p>0.05, N=3).

To confirm the role of ADRB2 in stress hormone mediated increase in small EV
release, the ADRB2-competent OVCAR5 and HeyA8 cells were treated with 1µM and
10µM of propranolol, a non-selective beta-blocker. After overnight serum starvation, 1µM
or 10µM of propranolol was added to HeyA8 and OVCAR5 cells. After 2 hrs, the cells were
treated with 10µM of NE. Supernatants were isolated from the cells after 12 hrs of NE
treatment, from which small EVs were isolated. There was no significant increase in small
EV secretion in the cells that were treated with both propranolol and NE, in comparison to
untreated controls (figure 19). These results show that the increase in small EV secretion
caused by treatment with NE indeed occurs via ADRB2 signaling. Since the aim of this
project is to study the changes in EV release caused by stress hormone-ADRB2 mediated
signaling, experiments to block the glucocorticoid receptor and study the effect on small EV
release were not performed.
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Figure 19: Pre-treatment with propranolol blocks NE-mediated increase in small EV
secretion.
There was no significant increase in small EV secretion from OVCAR5 and HeyA8 in
response to NE treatment when the cells were pre-treated with increasing concentrations of
propranolol (p>0.05, N=3).

4.5 Investigating the decrease in small EV secretion at long-term time points: serial
media isolation
At 48 hrs, both OVCAR5 and HeyA8 cell lines showed a decrease in small EV
secretion, which I hypothesized to be a result of either increased auto-uptake at that
timepoint, or a general decrease in production of EVs within the cells after 24hrs. To test
this hypothesis, the same OVCAR5 and HeyA8 cells were utilized to study EV release at all
timepoints rather than having a different set of cells and controls for every timepoint as done
previously. The rationale behind this approach was to observe whether periodically taking
out supernatant containing small EVs and replacing fresh serum free media on to the cells
would disrupt auto-uptake of EVs and cause an increase in the amount of secreted small EVs
in the supernatant in subsequent timepoints.
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Supernatant was isolated from the cells at 6 hrs replaced with new media, and so forth
for the 12 hrs, 24 hrs and 48 hrs timepoints as well. A second treatment of stress hormones
was given after fresh media was replaced at 12hrs, to account for the short half-life of
norepinephrine and cortisol in vitro. The isolated EVs were quantified by measuring protein
content using the Qubit Flex fluorometer. It was observed that there was a steady increase in
the small EV secretion with increasing amounts of stress hormones at all timepoints,
including at 48hrs (figure 20). This provided evidence of auto-uptake processes existing at
48hrs when the media hasn’t been serially replaced.

Figure 20: Serial isolation of media from HeyA8 and OVCAR5.
Serially isolating media from the same cells at different timepoints showed that there was a
steady increase in the small EV secretion from HeyA8 and OVCAR5 cells even at 48 hrs,
unlike what was observed in the previous experiments without serial media isolation
(p<0.05, N=3).
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4.6 Auto-uptake of small EVs
At 48hrs, increasing amounts of stress hormones decrease the small EV secretion
with respect to controls, indicating that stress hormone treatment might be conditioning the
cells or the EVs themselves for more uptake when compared to controls. To investigate this
further, a small EV uptake experiment was performed based on the protocol described
before. OVCAR5 and HeyA8 cells were grown and treated with 10µM of NE. At 48hrs, the
supernatant was discarded and fresh serum free medium was added along with either
labelled control small EVs or stress hormone-derived small EVs to control and NE-treated
cells respectively. After 6 hrs, the cells were washed, fixed and mounted (described in
methods) and visualized by confocal microscopy. It was seen that the NE-treated cells had
~3-fold higher uptake of EVs at 48hrs when compared to control cells (figure 21).

DAPI Cellmask bright red
Figure 21: NE-treated cells uptake more EVs at 48hrs.
NE-treated cells exposed to stress-derived EVs at 48 hrs took up more EVs than control
cells exposed to control EVs (p<0.05, N=3). EV uptake was measured as fluorescence
intensity of EV particles per field.
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However, this did not completely explain the decrease in small EV secretion at 48hrs.
The extent of EV uptake at earlier time points like 12hrs and 24hrs might also be the same
as that at 48hrs but there was no decrease in small EV secretion observed at those timepoints. Hence, this uptake experiment was repeated at an earlier time-point, 12hrs. OVCAR5
and HeyA8 cells were grown and treated with 10µM NE for 12hrs. The rest of the steps in
the uptake experiment were the same as those performed at 48hrs. As seen at 48hrs, NEtreated cells had more uptake of EVs than control cells, and the extent of uptake was similar
to that at 48hrs (~ 3-fold, p=0.03) [figure 22].

DAPI Cellmask bright red
Figure 22: NE-treated cells uptake more EVs at 12hrs.
NE-treated cells exposed to stress-derived EVs at 12 hrs took up more EVs than control cells
exposed to control EVs (p<0.05, N=3). The extent of uptake of EVs by NE-treated cells at 12
hrs was almost the same as that at 48 hrs (~ 3-fold). EV uptake was measured as
fluorescence intensity of EV particles per field.
This suggested that the decrease in small EV secretion at 48hrs was not due to uptake
of EVs, but due to a general decrease in production within the cell after being in serum free
media for an extended duration of time. The extent of uptake of EVs at 12hrs is similar to
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what was observed at 48hrs, however, the cells used at the 12hrs timepoint had been
growing in serum free media for a shorter duration, thereby having more cellular energy
supplies for production of EVs.

4.7 Effect of stress hormones on small EV quality – effect of stress-derived EVs on
cancer cell invasion
The second aim of this study is to determine the effects of stress-derived EVs on the
tumor microenvironment. Towards this, invasion assays were performed to study the effect
of control and stress-derived small EVs on ovarian cancer cell invasion. Ovarian cancer cells
and 20µg of EV proteins were placed in the upper chamber of the transwell coated with
Matrigel. The membranes were stained, mounted and visualized after 24hrs. It was observed
that stress-derived EVs promoted greater invasion of ovarian cancer than control EVs
(p=0.022) [figure 23].

Figure 23: Stress-derived EVs promote greater invasion than control EVs.
Invasion assay was performed with OVCAR5 cells and control and stress-derived OVCAR5
EVs. Stress-derived EVs promoted higher invasion of OVCAR5 cells than control EVs.
Invasion was measured as invading cells per high power field (p<0.05, N=3).
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4.8 Effect of stress hormones on small EV quality – effect of stress-derived EVs on tube
formation
Previous reports have shown that chronic stress and NE treatment promote in vivo
angiogenesis and tube formation (46). In order to compare the angiogenic potential of
control and stress-derived EVs, tube formation assays were performed as described before
with RF24 endothelial cells that were exposed to 20µg of EV proteins. Tube formation was
studied after 8hrs and it was observed that RF24 cells that were exposed to stress-derived
EVs formed more tubes than those exposed to control EVs (figure 24). These findings
suggest that stress-derived EVs might contain more factors that promote angiogenesis.

Figure 24: Stress-derived EVs promote greater tube formation than control EVs.
Tube formation assays performed on RF24 cells exposed to either control EVs or stressderived EVs showed that stress-derived EVs increase tube formation by almost 2-fold. Tube
formation was measured by counting the number of nodes formed by intersecting tubes per
high power field (p<0.05, N=4).

4.9 Effect of small EVs on functional assays
The in vitro assays performed to study the effect of stress-derived EVs on the tumor
microenvironment have all been performed under highly controlled conditions, with the
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amount of EV proteins and cell numbers being regulated. In the biological context, however,
processes like invasion and angiogenesis might be influenced by the number of circulating
tumor cell-derived EVs. Hence, it is important to account for the effect of EV number on
these processes in vitro. In order to accomplish this, the rationale was to treat ovarian cancer
cells with NE and an EV secretion inhibitor and use the conditioned media for the functional
assays instead of the EVs. This way, the number of EVs would be controlled by the
treatment given to the cells, and the outcome of the functional assays would depend on the
EV numbers.
First, ovarian cancer cells were treated with two EV secretion inhibitors, tipifarnib
and ketoconazole. 2hrs later, they were treated with NE. Supernatant was collected 12hrs
after NE treatment and EV number was calculated. Both tipifarnib and ketoconazole were
seen to decrease EV secretion by almost 40% even when the cells were treated with NE
(figure 25). This experiment showed that the inhibitors are efficient in reducing secretion of
EVs.

Figure 25: Tipifarnib and ketoconazole decrease EV secretion.
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Pre-treatment of HeyA8 cells with tipifarnib or ketoconazole followed by exposure to
norepinephrine decreased small EV secretion by approximately 40% (p<0.001, N=3).

Next, an invasion assay was performed with ovarian cancer cells that were treated
with conditioned media from 1) control ovarian cancer cells 2) Cells treated with NE and 3)
cells treated with NE and tipifarnib. It was observed that invasion was reduced in the cells
exposed to conditioned media with NE and tipifarnib (figure 26), with respect to the cells
exposed to conditioned media with only NE.

Figure 26: Changes in invasion driven by small EV number.
Cells exposed to conditioned media from NE-treated cells invaded more than the cells
exposed to control conditioned media or serum free media. Invasion of cells exposed to
conditioned media from tipifarnib and NE-treated cells was significantly lower than that of
cells exposed to conditioned media from only NE-treated cells (p<0.001, N=4).

Similarly, a tube formation assay was performed with RF24 cells co-cultured with
the same conditioned media as described above. Cells co-cultured with conditioned media
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containing both NE and tipifarnib had reduced formation of tubes with respect to the cells
only exposed to NE (figure 27).

Figure 27: Changes in tube formation driven by small EV number.
Tube formation in RF24 cells exposed to conditioned media from cells treated with both
tipifarnib and NE was significantly lower than that in RF24 cells exposed to conditioned
media from NE-treated cells (p<0.05, N=4).

These results indicate that EV number has effects on processes like invasion and tube
formation. In the biological context, this could be significant because chronic stress would
increase the number of circulating tumor-derived EVs.
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4.10 In vivo angiogenic capacity of stress-derived small EVs
Since stress-derived cancer cell EVs drive more tube formation in vitro, I sought to
validate these findings in vivo by performing a Matrigel plug assay. There were 4 treatment
groups for this experiment:
1. Serum free media (negative control)
2. Conditioned media from control ovarian cancer cells
3. Conditioned media from NE-treated cancer cells
4. VEGF-A (positive control)
The conditioned media from cells were centrifuged as per the EV isolation protocol to get
rid of cell debris and large vesicles but ultracentrifugation was not done. Nude mice
(3/group) were injected subcutaneously with a 2:3 combination of media and growth factorreduced Matrigel. The mice were sacrificed after 8 days and the Matrigel plugs were
collected. The extent of angiogenesis was estimated by quantifying the hemoglobin content
in the plugs (described in methods). It was observed that the hemoglobin content in plugs
that contained conditioned media with NE had significantly higher hemoglobin than the
plugs with control conditioned media (figure 28). This suggests that NE-derived EVs might
have a role in chronic stress-induced angiogenesis in ovarian cancer.
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Figure 28: Measurement of angiogenesis stimulated by control and stress-derived EVs in
vivo.
Hemoglobin content in Matrigel plugs containing conditioned media from NE-treated cells
was significantly higher than that observed in plugs containing control conditioned media
(p<0.05, N=3). The right panel shows the subcutaneous Matrigel plugs retrieved from the
mice.

4.11 MS analysis of control and stress-derived small EVs
Since stress-derived EVs can promote oncogenic processes to a greater extent than
control EVs, it was necessary to understand the differences in the contents of these two
types of EVs to explain the phenotypic effects that were observed. A mass spectrometry
analysis was performed on the control and stress-derived small EVs and the raw data was
analyzed using Ingenuity Pathway Analysis (IPA). When the number of proteins unique to
each group was analyzed, around 50% of proteins in each group were unique, while the rest
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were common between both groups (figure 29). This could be explained by the fact that the
source cells for both groups of EVs were the same, hence a lot of the proteins might be
common between both groups.

Figure 29: Comparison of the number of proteins in control and stress-derived small EVs.
145 proteins were commonly found in both control and stress-derived EVs whereas 51 and
85 proteins were uniquely expressed in the control and stress-derived EVs respectively.

Next, the 51 unique proteins of the control EVs and the 85 unique proteins of NEderived EVs were compared to see the differences in their functions and the biological
processes they are involved in. The stress-derived EVs had significant enrichment of
proteins involved in cell growth and maintenance when compared to control EVs (figure
30). Other processes such as cell communication, signal transduction and protein
metabolism were also investigated, to see if there was preferential enrichment of proteins
involved in these processes in the EV groups. No statistically significant enrichment was
found.
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Figure 30: Differentially enriched proteins and their biological functions.
A comparison of the selective protein expression in either stress-derived or control EVs with
the overall protein content in stress-derived EVs or control EVs respectively. There was a
significant enrichment of cell growth and maintenance-related proteins in stress-derived
EVs alone (p=0.007).

Since there was a statistically significant enrichment of cell growth-related proteins
in NE-derived EVs, the data was further analyzed to find out specific proteins that might be
involved in the phenotypic effects that were seen in the previous experiments (figure 31).
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Figure 31: Major proteins in stress-derived small EVs that are involved in cell growth and
angiogenesis.
The proteins selectively expressed only in stress-derived EVs were mapped to identify
potential proteins of interest involved in cell growth-related pathways.

The two major upstream proteins that showed up in this search were ERBB2 and
TNFRSF1A. TNFRSF1A is also known to be a modulator of angiogenesis, which could
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explain why stress-derived EVs could promote greater tube formation in vitro. Cell growth
and maintenance proteins like ERBB2 may also modulate growth of endothelial cells when
transferred through EVs, hence the pro-angiogenic effect of NE-derived EVs could also be
because of enhanced growth of endothelial cells and not necessarily due to a pro-angiogenic
protein in the EVs. Overall, the protein content unique to NE-derived EVs indicate that they
have the capacity to drive cell growth in the recipient cells.
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Chapter 5 – Summary and discussion
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5.1 Summary
The stress hormones NE and hydrocortisone promote secretion of small EVs from
high grade serous ovarian cancer cells in vitro, at 12hrs and 24hrs post treatment. At 48
hours, there is a decrease in the EV secretion from the cancer cells on treatment with the
stress hormones, which could be due to an overall decrease in production of EVs within the
cells and not due to increased uptake of EVs by the cancer cells. The increases in EV
secretion are dependent on signaling through the ADRB2 receptor. ADRB2-null cell lines
and cells treated with beta-blockers do not increase secretion of small EVs upon treatment
with stress hormones.
Stress-derived EVs promote oncogenic processes such as invasion of cancer cells
and tube formation of endothelial cells in vitro when compared to control EVs. These
observations are dependent on the EV number in the biological context, as seen in the
reduction in invasion and tube formation when conditioned media from cells treated with
EV-secretion inhibitors are used in the experiment. Stress-derived EVs might promote
angiogenesis in vivo, based on hemoglobin content in Matrigel plugs with or without
conditioned media from NE-treated cells. Proteomic analysis of the control and NE-derived
EVs showed that the NE-derived EVs have enrichment of proteins involved in cell growth
and maintenance. These enriched proteins might be responsible for the pro-angiogenic
effects of stress-derived EVs which might be getting transferred from the EVs to the
endothelial cells.
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5.2 Discussion
There is growing evidence to implicate the role of adrenergic signaling in driving
malignant progression and negatively affecting patient survival and outcome to therapy.
Various pre-clinical and clinical studies done in different cancer types have shown that
norepinephrine-mediated signaling activates pro-metastatic and tumorigenic networks.
However, mechanisms involved in these stress-driven oncogenic processes have not been
fully understood. In this thesis, the focus was on finding a relationship between
norepinephrine secretion and the release and biological activity of extracellular vesicles,
another widely studied cause of tumor growth, metastasis and inflammation.
Work done in this project shows that the stress-mediators norepinephrine and cortisol
can increase the secretion of EVs from ovarian cancer cells. These stress-shaped EVs have
the capacity to drive several oncogenic processes like invasion and angiogenesis, thereby
implying that the tumor-promoting effects of chronic stress could be occurring via EVs.
While there is previous in vivo and patient data to indicate that psychosocial factors and
stressors might alter EV cargo (121,122), the results of this project provide experimental
proof in support of this concept.
Data from this project consistently shows that stress-derived EVs increase
angiogenesis, and that there is selective enrichment of cell-growth related proteins in stressderived EVs. While it could be argued that there should be enrichment of angiogenesis
related proteins in stress-derived EVs to support the results, the enrichment of cell growthrelated proteins can also be interpreted as a driver of endothelial cell proliferation leading to
increased tube formation and angiogenesis. This project did not have experiments to show
that stress-derived EVs can increase cell proliferation but studies can be conducted in the
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future to observe if cancer cells and endothelial cells proliferate more on exposure to stressderived cancer cell EVs than control cancer EVs. Specific mechanisms of angiogenesis
induced by stress-derived EVs were not identified in this project, and this can be
accomplished by conducting pathway analysis on endothelial cells exposed to EVs and
correlating the data with the EV proteomic analysis.
The tumor microenvironment is a diverse milieu, and is comprised of several cells,
including macrophages, immune cells, endothelial cells, platelets and cancer-associated
fibroblasts. The ADRB2 receptor is almost ubiquitously expressed in the body (18,19),
which indicates that norepinephrine released due to chronic stress could affect the cells of
the microenvironment as well. Uptake studies done in this project show that NE-treated
cancer cells take up more EVs than untreated cells. This finding when applied to other types
of cells could explain several biological outcomes of chronic stress such as immune
suppression and increased metastasis. In the biological context, cells could uptake not only
their own EVs but also the EVs secreted by neighboring cells. This gives us ample
opportunity to study the interactions between stress-shaped EVs and the cells in the
microenvironment which may engage in a complex interplay to further tumor progression.
Data from the project indicate that stimulation of cancer cell invasion and endothelial
tube formation by EVs is driven by EV numbers, as observed in the experiments conducted
by exposing cancer cells and endothelial cells to conditioned media of cancer cells treated
with norepinephrine and/or EV secretion inhibitor (tipifarnib). Exposure to conditioned
media from cells treated with both norepinephrine and tipifarnib showed a decrease in
invasion and tube formation when compared to the cells that were exposed to conditioned
media from norepinephrine treated cells. These findings indicate that regulation of EV
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numbers could dampen oncogenic processes like invasion and angiogenesis. EV secretion
inhibitors can be used to abrogate chronic stress-induced increase in EV release in vivo and
tumor burden can be monitored. Data from such studies could be relevant for reducing
chronic stress-induced malignant progression in patients.
In conclusion, ADRB2-mediated signaling can elicit biological effects in cancer by
shaping the EVs secreted by cancer cells. Further understanding of the functions of stressderived EVs in the microenvironment could lead to identification of newer strategies to
attenuate stress-induced cancer progression.
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